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ABSTRACT
Imgatuzumab is a novel glycoengineered anti-epidermal growth factor receptor 
(EGFR) monoclonal antibody optimized to induce both antibody-dependent cellular 
cytotoxicity (ADCC) and EGFR signal transduction inhibition. We investigated anti-
EGFR monoclonal antibodies imgatuzumab and cetuximab–induced internalization and 
membranous turnover of EGFR, and whether this affected imgatuzumab–mediated 
ADCC responses and growth inhibition of non-small cell lung cancer (NSCLC) cells.
In a panel of wild-type EGFR expressing human NSCLC cell lines, membranous 
and total EGFR levels were downregulated more effectively by imgatuzumab 
when compared with cetuximab. Imgatuzumab plus cetuximab enhanced EGFR 
internalization and reduced membranous turnover of EGFR, resulting in an even 
stronger downregulation of EGFR. Immunofluorescent analysis showed that 
combined treatment increased clustering of receptor-antibody complexes and 
directed internalized EGFR to lysosomes. The antibody combination potently inhibited 
intracellular signaling and epidermal growth factor (EGF)-dependent cell proliferation. 
More importantly, robust EGFR downregulation after 72 hours with the antibody 
combination did not impair ADCC responses.
In conclusion, imgatuzumab plus cetuximab leads to a strong downregulation of 
EGFR and superior cell growth inhibition in vitro without affecting antibody-induced 
ADCC responses. These findings support further clinical exploration of the antibody 
combination in EGFR wild-type NSCLC.
INTRODUCTION
The epidermal growth factor receptor (EGFR), a 
member of the human epidermal growth factor receptor 
(HER) family of receptor tyrosine kinases, is an important 
regulator of cell growth and differentiation. Upon 
ligand binding, EGFR homodimerizes or interacts with 
other HER members, i.e. HER2 and HER3, to form 
heterodimers. This results in activation of downstream 
signaling cascades such as the RAS-ERK pathway and 
PI3K/Akt pathway, thereby controlling many biological 
processes. These pathways are frequently dysregulated 
via overexpression, autocrine stimulation, crosstalk with 
other receptors and/or mutations, and play a pivotal role 
in multiple tumor types [1].
Targeting EGFR is an important treatment modality 
for many solid tumors including non-small cell lung cancer 
(NSCLC). Treatment strategies to target EGFR consist 
of tyrosine kinase inhibitors (TKIs) and monoclonal 
antibodies. At present, EGFR TKIs are standard of care 
for NSCLC patients with EGFR-mutated tumors as first- 
and second-line treatments [2]. Cetuximab (IgG1 subtype) 
is an anti-EGFR monoclonal antibody approved by the 
Food and Drug Administration USA for colorectal cancer 
and head and neck squamous cell cancer. Anti-EGFR 
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monoclonal antibody panitumumab (IgG2 subtype), on 
the other hand, is approved for treatment of colorectal 
cancer. These monoclonal antibodies can exert their action 
via a variety of mechanisms, including blocking (hetero)
dimerization and ligand binding, as well as inducing EGFR 
endocytosis, complement dependent cytotoxicity (CDC) 
and antibody-dependent cellular cytotoxicity (ADCC) 
[3–7]. ADCC is usually considered an important 
mechanism of action for immunotherapy with human 
IgG1 but not IgG2 antibodies. Recent evidence 
suggests that addition of cetuximab to chemotherapy 
in first line improves overall survival of patients with 
EGFR-expressing advanced NSCLC [8]. Interestingly, 
retrospective analyses revealed that mutational status and 
copy number of EGFR were not predictive for cetuximab 
benefit [9]. Therefore, treatment of EGFR wild-type 
NSCLC with anti-EGFR monoclonal antibodies might 
be of interest. Unfortunately, the impact of cetuximab 
on survival is small and the prognosis of advanced 
NSCLC remains poor. There is a continuous need for new 
treatments to improve survival. A stronger inhibition of 
EGFR or higher level of ADCC can potentially contribute 
to this improvement.
Anti-EGFR monoclonal antibody combinations can 
enhance endocytic downregulation of EGFR, and these 
combinations showed superior anticancer efficacy in several 
human tumor xenograft models, including triple negative 
breast cancer and EGFR-mutant NSCLC [10-12]. A higher 
level of ADCC can be achieved by glycoengineering the Fc 
region of a therapeutic antibody. Imgatuzumab (GA201) is 
a novel glycoengineered anti-EGFR monoclonal antibody 
of the IgG1 subclass, which is optimized to induce ADCC 
and inhibits EGFR signal transduction [13]. Imgatuzumab 
showed superior preclinical in vivo efficacy compared 
with cetuximab and non-glycoengineered imgatuzumab 
in both KRAS-mutant and KRAS wild-type models 
[13]. The clinical benefit of combining two monoclonal 
antibodies against EGFR is still unknown. Clinical benefit 
of combining antibodies has already been demonstrated for 
another HER family member, HER2, in breast cancer using 
the anti-HER2 antibodies trastuzumab and pertuzumab 
[14-16]. Trastuzumab binds to HER2 and suppresses 
its signaling capability. Pertuzumab complements the 
mechanism of action of trastuzumab by binding to another 
epitope of HER2, which inhibits the dimerization of HER2 
with other HER receptors.
Imgatuzumab and cetuximab are directed against 
distinct, non-overlapping epitopes in EGFR extracellular 
domain III [13]. Thus, the combination of both antibodies 
is a potential strategy to target EGFR more effectively than 
existing clinical single antibody treatments. It is unknown 
whether treatment with imgatuzumab or the combination 
with cetuximab increases EGFR internalization and/or 
reduces membranous turnover of EGFR in cancer cells, 
potentially diminishing ADCC responses. The aim of 
the present study was therefore to investigate the effects 
of imgatuzumab and cetuximab on EGFR dynamics, 
intracellular signaling and survival in a panel of human 
EGFR wild-type NSCLC cell lines. Finally, we monitored 
whether changes in EGFR dynamics affect ADCC 
responses and tumor cell growth inhibition.
RESULTS
Imgatuzumab combined with cetuximab strongly 
downregulates EGFR expression in NSCLC cells
All NSCLC cell lines expressed EGFR, with the 
highest cell surface levels found in H292 cells (Figure 1A). 
Addition of cetuximab to imgatuzumab resulted in a 
nearly two-fold increase in mean fluorescence intensity 
of membranous EGFR (Figure 1A), which is in line 
with previous findings that imgatuzumab and cetuximab 
are binding to non-overlapping epitopes in EGFR 
extracellular domain III [13]. Next, we measured EGFR 
levels following incubation of cells with imgatuzumab 
and cetuximab alone or combined for 72 hours. In the 
presence of imgatuzumab, membranous EGFR levels 
were diminished by 38% in SW-1573 and up to 75% for 
A549, whereas cetuximab had less effect (up to 26% for 
A549) (Figure 1B). Treating cells with the combination 
of monoclonal antibodies resulted in a stronger 
downregulation of membranous EGFR levels ranging 
from 65% in SW-1573, up to 89% for A549. Similar 
results were observed with 24 hours incubation or twice 
the amount of each monoclonal antibody (Supplementary 
Figure 1A), which suggests an equilibrium in membranous 
turnover of EGFR. A non-glycoengineered GA201 
(GA201wt) was used to investigate the effect of antibody 
glycoengeneering on EGFR surface expression. GA201wt 
and imgatuzumab had similar effects on membranous 
EGFR in SW-1573 and H292 cells, excluding the 
involvement of glycoengeneering (Supplementary 
Figure 1B).
Western blot analyses demonstrated that treatment 
of SW-1573, H292 and A549 cells with imgatuzumab 
alone or combined with cetuximab led to a decrease in 
total cellular EGFR protein levels as well (Figure 2). Both 
single agents and the combination efficiently inhibited 
EGF-induced phosphorylation of downstream signaling 
molecules such as Akt and ERK1/2 (Figure 2 and 
Supplementary Figure 2). In H292, only the combination 
was able to completely inhibit EGF-induced Akt and 
ERK1/2 phosphorylation. Interestingly, treatment 
with imgatuzumab or cetuximab increased EGFR 
phosphorylation at Tyr1068 and Tyr1173, but did not 
lead to increased phosphorylation of Akt or ERK1/2. 
Despite a lower level of phosphorylated EGFR at both 
phosphorylation sites, EGF was able to activate EGFR 
downstream signaling in contrast to imgatuzumab or 
cetuximab. Addition of cetuximab to imgatuzumab 
counteracted the increase in EGFR phosphorylation. 
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Figure 1: Effect of anti-EGFR monoclonal antibody treatment on EGFR surface expression levels. (A) Flow cytometric 
analysis of imgatuzumab and cetuximab binding alone or in combination in H322, SW-1573, H441, H292 and A549 cells. (B) H322, 
SW-1573, H292, H441 and A549 cells were treated with the anti-EGFR monoclonal antibodies (20 µg/mL total) for 72 hours. Surface 
expression levels were determined using flow cytometry. The surface expression in untreated control cells was set at 100% both for the 
single antibodies and the combination. (*P < 0.05, **P < 0.01 combination vs imgatuzumab; $P < 0.05, $$P < 0.01, $$$P < 0.001 combination 
vs cetuximab; unpaired t-test). Data points are mean + SD (n = 3).
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GA201wt and imgatuzumab had similar effects on EGFR 
protein levels and phosphorylation in SW-1573 and H292 
cells (Supplementary Figure S3A).
Taken together these results indicate a strong 
reduction in EGFR cell surface expression and total 
cellular EGFR expression by continuously exposing cells 
to imgatuzumab, which was not observed with cetuximab. 
Combining imgatuzumab with cetuximab augments the 
reduction in EGFR expression.
Imgatuzumab combined with cetuximab 
enhances EGFR internalization and reduces 
EGFR turnover at the plasma membrane
Flow cytometry was used to determine whether 
the downregulation of EGFR is due to enhanced 
internalization of this receptor. SW-1573 and H292 
cells were pre-loaded with imgatuzumab and cetuximab 
on ice and subsequently incubated at 37 °C for the 
indicated time points. Experiments with radiolabeled 
monoclonal antibodies showed a minimal release of 
monoclonal antibodies from cells during 4 hours (results 
not shown), indicating that antibody internalization is a 
measurement of EGFR internalization. Imgatuzumab and 
cetuximab were internalized at similar rates in SW-1573 
(Figure 3A) and H292 cells (Figure 3B), as demonstrated 
by a decrease in non-internalized EGFR-antibody 
complexes. GA201wt and imgatuzumab had similar effects 
on EGFR internalization and surface levels in SW-1573 
and H292 cells (Supplementary Figure 3B). Despite the 
rapid internalization of these complexes, overall EGFR 
cell surface levels marginally changed by single antibody 
treatment, indicating that membranous turnover of EGFR 
was not rate limiting within this timeframe. Imgatuzumab 
in combination with cetuximab, however, accelerated 
EGFR internalization in SW-1573 and H292 cells, which 
resulted in a strong reduction of overall EGFR cell surface 
levels. Pretreatment with the protein synthesis inhibitor 
cycloheximide reduced basal EGFR surface levels. 
However, the percentage internalized antibody–EGFR 
complexes and the percentage EGFR surface expression 
on SW-1573 and H292 cells after 2 hours incubation 
Figure 2: Western blot analysis of the effect of 24 hours anti-EGFR monoclonal antibody treatment on EGFR total 
protein levels and downstream signaling under normal growth conditions or 15 min EGF stimulation (10 ng/mL). The 
immunoreactive spots were quantified by densitometric analysis and normalized using actin (see also Supplementary Figure 2). Values are 
expressed as fold increase versus control + SD. All experiments were performed in triplicate.
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with antibodies at 37 °C were proportionally similar to 
the results in antibody-treated cells without cycloheximide 
pretreatment (results not shown). These findings indicate 
that, within this 2 hours timeframe, the absolute level 
of membranous EGFR was affected by cycloheximide 
treatment, whereas the kinetics of antibody-induced 
internalization and (re)appearance of EGFR on the cell 
surface was predominantly determined by the antibody used.
EGFR tyrosine kinase inhibition by erlotinib does 
not affect EGFR internalization and degradation 
by imgatuzumab combined with cetuximab
We sought to determine whether imgatuzumab-
induced EGFR phosphorylation is instrumental in the 
strong reduction in EGFR protein levels. SW-1573, 
H292 and A549 cells were treated with erlotinib to 
inhibit EGFR tyrosine kinase activity. Co-treatment 
of cells with erlotinib and the monoclonal antibodies 
individually for 24 hours showed that erlotinib indeed 
reduced p-EGFR levels (Figure 4A). Interestingly, 
erlotinib inhibited imgatuzumab-induced EGFR protein 
degradation, but had no effect on EGFR degradation by 
the antibody combination. It should be noted that erlotinib 
treatment alone increased EGFR expression in H292 and 
A549 cells, which makes these results more difficult to 
interpret. To investigate the influence of EGFR kinase 
activity on monoclonal antibody-induced internalization 
in a short-term experiment, SW-1573 cells were pretreated 
for 24 hours with erlotinib. Erlotinib did not reduce 
Figure 3: Influence of monoclonal antibody binding on EGFR internalization and surface expression. SW-1573 (A) and 
H292 cells (B) were surface labeled with the anti-EGFR monoclonal antibodies on ice and incubated at 37 °C for the indicated times, and 
then analyzed for the non-internalized EGFR-antibody complexes (left) and cell surface expression (right). The lower the amount of non-
internalized EGFR-antibody complexes, the higher the amount of internalized antibody-EGFR complexes. The surface expression at t=0 
was set at 100%. The non-internalized and surface expression were determined as described in Materials and Methods (n=3). Data points 
are mean ± SD. (**P < 0.01, ***P < 0.001 combination vs imgatuzumab; $$P < 0.01, $$$P < 0.001 combination vs cetuximab; two-way 
ANOVA followed by Bonferroni post-test).
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internalization of antibody-EGFR complexes (Figure 4B). 
In fact, total EGFR surface expression was significantly 
reduced when the antibody combination was added to 
erlotinib-pretreated cells. These results demonstrate 
that p-EGFR inhibition is not antagonizing EGFR 
internalization and degradation induced by the antibody 
combination.
Imgatuzumab combined with cetuximab 
increases clustering of EGFR-antibody 
complexes and targets EGFR to the lysosomal 
degradation pathway
The intracellular localization of EGFR after antibody 
treatment was investigated with immunofluorescent 
microscopy, focusing on the endocytic and lysosomal 
degradation pathways. Staining of SW-1573 cells with 
imgatuzumab and/or cetuximab as primary antibodies 
clearly showed membranous EGFR fluorescence 
(Figure 5A). SW-1573 and H292 cells were subsequently 
incubated with the anti-EGFR monoclonal antibodies on 
ice and then chased for 4 hours at 37 °C. Imgatuzumab and 
cetuximab localized to internal vesicles (Figure 5A and 
Supplementary Figure 4B). To exclude the possibility that 
the incubation with secondary antibodies triggers cluster 
formation due to crosslinking of monoclonal antibodies, 
SW-1573 cells were incubated with imgatuzumab directly 
labeled with Dylight 633. Cluster formation was still 
observed when imgatuzumab Dylight 633 was combined 
with cetuximab (Supplementary Figure 4A). We then 
stained SW-1573 and H292 cells for EEA1, a marker for 
early endosomes. Imgatuzumab and cetuximab mostly 
Figure 4: Effects of TKI treatment on monoclonal antibody-induced internalization and degradation. (A) Western blot 
analysis of the effect of 24 hours anti-EGFR monoclonal antibody treatment (20 µg/mL total) with or without erlotinib (10 µM) on EGFR 
total protein levels in SW-1573, H292 and A549. Data points are mean + SD. (*P < 0.05, **P < 0.01, ***P < 0.001 compared to untreated 
control; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared to erlotinib treated control). (B) SW-1573 cells were pretreated for 24 hours with the 
EGFR TKI inhibitor erlotinib (10 µM). Cells were subsequently surface labeled with the anti-EGFR monoclonal antibodies (20 µg/mL 
total) on ice and incubated at 37 °C for 4 hours, and then analyzed for the non-internalized EGFR-antibody complexes (NI) and cell surface 
expression (SE). The lower the amount of non-internalized EGFR-antibody complexes, the higher the amount of internalized antibody-
EGFR complexes. Surface expression of the control and erlotinib treated cells were both set at 100%. 24 hours erlotinib treatment resulted 
in a slight upregulation (10 – 15 % increase). Data points are mean ± SD (n = 3). (*P < 0.05).
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co-localized with EEA1-positive vesicles, indicating 
internalized monoclonal antibodies (Figure 5A and 
Supplementary Figure 4B). Following incubation of cells 
for 4 hours at 37 °C, the antibody combination localized 
to large clusters at the surface and/or intracellular vesicles 
(Figure 5A and Supplementary Figure 4B). In cells treated 
Figure 5: Cellular localization and endocytic trafficking of anti-EGFR monoclonal antibodies in SW-1573. (A) Cells 
were surface labeled with the anti-EGFR monoclonal antibodies (mAbs) on ice. After staining with the primary antibody cells were washed 
with ice-cold FACS buffer and incubated for 4 hours at 37 ˚C. After fixation, permeabilization, and incubation with anti-EEA1 and anti-
Lamp1 antibodies, cells were incubated with fluorescent secondary antibodies (anti-human Alexa 488 against imgatuzumab and cetuximab 
(green color), Alexa 647-labeled antibodies for endosomal markers (red color)). For the Lamp1 staining additional anti-EGFR monoclonal 
antibodies were added to visualize total EGFR. Colocalization appears as yellow (merged images). Images were acquired using a confocal 
microscope. White scale bars represent 10 µm. (B) Western blot analysis of the effect of lysosomal inhibition on monoclonal antibody-
induced EGFR degradation. SW-1573 cells were pretreated for 2 hours with the lysosomal inhibitor bafilomycin A1 (100 nM). Cells were 
subsequently treated with the anti-EGFR monoclonal antibodies (20 µg/mL total) for 4 hours. Data points are mean + SD. (**P < 0.01 
compared to control).
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with imgatuzumab combined with cetuximab, antibody-
positive vesicles were only partially co-localizing with 
EEA1-positive vesicles, suggesting that the EGFR 
antibody combination complexes are localized in a 
different compartment. Therefore, cells were stained for 
LAMP1 to identify the lysosomal compartment. The 
monoclonal antibodies did not co-localize with lysosomes 
(data not shown), which may be due to degradation of 
receptor antibody-complexes in lysosomes. Adding 
additional anti-EGFR monoclonal antibodies after 
fixation showed that EGFR predominantly co-localized 
with lysosomes in cells treated with both imgatuzumab 
and cetuximab (Figure 5A and Supplementary Figure 4B). 
Blocking lysosomal proteolysis by bafilomycin A1 largely 
prevented monoclonal antibody combination-induced 
EGFR degradation in SW-1573 (Figure 5B) and A549 cells 
(Supplementary Figure 4C). However, EGFR degradation 
by monoclonal antibody combination treatment was 
only partially prevented in H292 cells (Supplementary 
Figure 4C). Taken together, these results show that the 
strong downregulation after treatment with imgatuzumab 
alone and combined with cetuximab is at least partially the 
result of directing EGFR to lysosomes. These observations 
are consistent with findings of Ferraro et al. showing that 
anti-EGFR monoclonal antibody mixtures accelerate 
lysosomal degradation of EGFR [12].
Imgatuzumab combined with cetuximab 
effectively inhibits EGF-dependent cell 
proliferation
Next, the antiproliferative effect of imgatuzumab 
and cetuximab on SW-1573, H292, H322, H358 and 
A549 cells was investigated. Under normal culture 
conditions (media with 10% FCS), both single agents 
and the combination strongly inhibited H292 and H322 
cell proliferation (Figure 6). The antiproliferative effects 
in H292 correlated with strong inhibition of downstream 
signaling after monoclonal antibody treatment 
(Figure 2). To investigate the growth inhibitory potential 
of the monoclonal antibodies in the presence of additional 
EGF, H292, H322 and A549 cells were incubated with 
imgatuzumab, cetuximab or the combination under normal 
culture conditions supplemented with physiological 
concentrations of EGF. Imgatuzumab was more effective 
than cetuximab in inhibiting proliferation in media 
supplemented with 1 ng/mL EGF. Addition of 10 ng/mL 
EGF to media induced complete resistance to the single 
antibody treatments, whereas the antibody combination 
was still able to almost completely inhibit proliferation. 
As expected, no clear effects of imgatuzumab and 
cetuximab on proliferation were observed in KRAS-
mutant A549 (Figure 6) and SW-1573 cells (results not 
shown). Interestingly, under normal growth conditions and 
supplemented with 1 ng/mL EGF, imgatuzumab alone and 
combined with cetuximab partially inhibited proliferation 
of KRAS-mutant H358 cells (Supplementary Figure 5). 
Under conditions of high EGF, only the combination 
inhibited proliferation.
Both single antibody treatments and the combination 
completely inhibited EGF-dependent migration of H292 
and A549 cells as measured with the wound-healing assay 
(Supplementary Figure 6).
Imgatuzumab combined with cetuximab induces 
strong ADCC but no CDC responses against 
NSCLC cells
Imgatuzumab combined with cetuximab is the 
most potent in downregulating EGFR surface expression. 
However, effective EGFR downregulation might impair 
imgatuzumab-dependent ADCC responses. Alternatively, 
imgatuzumab and cetuximab are noncompetitively binding 
to EGFR (Figure 1A), which may even result in stronger 
ADCC responses. We performed an in vitro ADCC assay, 
in which human peripheral blood mononuclear cells 
(PBMCs) were used as effector cells and H441, H292 or 
A549 cells as target cells. When applied as single agent, 
imgatuzumab caused superior ADCC against NSCLC 
cells compared with cetuximab (Figure 7A-7C). No 
increase in ADCC responses was observed when the two 
monoclonal antibodies were combined. Next, the effect 
of EGFR downregulation on the ADCC response after 
long-term treatment with imgatuzumab was investigated 
in A549 cells. These cells were chosen based on the 
strong downregulation of membranous EGFR (Figure 1B) 
and their resistance to anti-EGFR monoclonal antibody 
treatment under normal growth conditions to avoid anti-
proliferative effects (Figure 6). Pretreatment of cells with 
imgatuzumab for 72 hours did not alter ADCC responses 
despite the strong reduction in membranous EGFR 
(Figure 7D). Similar results were observed when cells 
were treated with imgatuzumab combined with cetuximab 
for 72 hours (Figure 7D).
Next, we investigated whether imgatuzumab 
and cetuximab induce CDC in our NSCLC cell line 
panel. For the in vitro CDC assay freshly drawn human 
serum was used. CDC was not induced in H292 and 
A549 with imgatuzumab or cetuximab, whereas a 
CDC response was observed in EGFR-amplified 
squamous-cell carcinoma A431 cells as positive control 
(Supplementary Figure 7). Addition of imgatuzumab to 
cetuximab significantly enhanced a CDC response in 
A431 cells only.
DISCUSSION
In the present study we show that glycoengineered 
imgatuzumab downregulated membranous and cellular 
EGFR protein levels, whereas cetuximab had almost no 
effect in a panel of EGFR wild-type expressing NSCLC 
cell lines. Dual EGFR targeting with imgatuzumab 
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in combination with cetuximab led to a stronger 
downregulation of membranous and cellular EGFR protein 
levels by lysosomal targeting of the receptor, while ADCC 
effects were maintained. In addition, blocking EGFR with 
imgatuzumab combined with cetuximab most effectively 
inhibited cell proliferation. Our results suggest a novel 
strategy combining imgatuzumab with cetuximab for lung 
tumors expressing wild-type EGFR.
Figure 6: In vitro growth-inhibitory effect of anti-EGFR monoclonal antibody treatment. Cells were seeded in 12-wells 
plates and allowed to adhere overnight. Next, H292, H322 and A549 cells were treated with the anti-EGFR monoclonal antibodies (20 µg/
mL total) for the indicated days under normal growth conditions without additional EGF (medium with 10% FCS) or in medium containing 
10% FCS with 1 or 10 ng/mL EGF. Data points are mean + SD. All experiments were performed in triplicate.
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The ability of imgatuzumab to internalize 
and downregulate EGFR is not related to antibody 
glycoengeneering but might be partially attributed to 
the increased auto-phosphorylation levels of EGFR. 
Several anti-EGFR monoclonal antibodies applied as 
single agents act as partial agonists due to their ability 
to force EGFR homodimerization and subsequent auto-
phosphorylation, leading to EGFR downregulation 
[12,17,18]. However, Gerdes et al. did not observe 
increased auto-phosphorylation levels after imgatuzumab 
treatment in A431 cells [13]. Furthermore, Cunningham 
et al., using the parental rat anti-EGFR antibody IRC62 
and DiFi cells, showed that the antibody reduces EGFR 
phosphorylation at multiple sites [19]. These discrepancies 
might be due to differences in cell lines and experimental 
set-up. For example, both A431 and DiFi cells overexpress 
EGFR as a result of extensive EGFR gene amplification. 
Furthermore, A431 cells were cultured in spheroids 
instead of a 2D monolayer, which might have influenced 
dimerization and signaling. Even though imgatuzumab 
and cetuximab induced EGFR Tyr1068 and Tyr1173 
phosphorylation in our experiments, it did not lead to 
increased phosphorylation of ERK1/2 and Akt. This is 
in line with previous findings that anti-EGFR antibodies, 
including cetuximab, can induce EGFR phosphorylation 
but fail to trigger downstream signaling in NSCLC and 
head and neck squamous cell carcinoma cell lines [17,18]. 
The absence of downstream signaling is also demonstrated 
by the fact that imgatuzumab was still capable of inhibiting 
cell proliferation with a similar potency as cetuximab. 
The inability of imgatuzumab and cetuximab to activate 
downstream signaling might be due to reduced antibody-
EGFR complex internalization compared with ligand-
EGFR complexes [17]. Probably, this interferes with 
signaling induced by internalized ligand-EGFR complexes, 
which can interact in the endosomal compartment with 
various downstream signaling proteins that are important 
for continuous activation of the major signaling pathways 
mediated by ERK [20, 21]. In addition, phosphorylation 
of EGFR on Tyr1173 might have a suppressive effect 
Figure 7: In vitro ADCC analysis of imgatuzumab, cetuximab or the combination. PBMCs as effector cells were added to the 
untreated H441 (A), H292 (B) or A549 (C) target cells at a ratio of 25:1. ADCC responses were normalized to the ADCC response of the 
highest imgatuzumab concentration due to variations in responses between PBMCs of different donors. Absolute ADCC responses ranged 
between 12 and 53%. (*P < 0.05, **P < 0.01, ***P < 0.001 cetuximab vs imgatuzumab). (D) A549 cells were pretreated with imgatuzumab 
alone (20 µg/mL) or combined with cetuximab (20 µg/mL total) in culture medium for 72 hours. Next, cells with (open triangle and open 
square) or without (solid triangle and solid square) antibody pretreatment for 72 hours were washed and the ADCC assay was performed 
using PBMCs as effector cells and A549 cells as target cells at a ratio of 25:1. Data points are mean ± SD (n = 3).
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on ERK signaling [22]. However, we cannot exclude 
the possibility that increased auto-phosphorylation after 
imgatuzumab or cetuximab treatment activates other 
downstream pathways of EGFR with unknown effects 
on NSCLC cells [23]. Interestingly, the combination of 
imgatuzumab and cetuximab counteracted the increase in 
EGFR auto-phosphorylation levels observed after single 
antibody treatment and, therefore, might be the preferred 
strategy to inhibit EGFR signaling.
Our experiments with EGFR TKI erlotinib 
demonstrate that imgatuzumab-induced EGFR protein 
degradation, but not EGFR internalization is related to 
EGFR kinase activity. Surprisingly, erlotinib did not affect 
EGFR degradation when imgatuzumab was combined 
with cetuximab. This discrepancy could be the result of 
different endocytic pathways that were activated, which 
may depend on the size of receptor-antibody complexes, 
or receptor ubiquitination [24]. For example, formation 
of large EGFR–antibody complexes at the cell surface 
was found to internalize EGFR by macropinocytosis, 
resulting in efficient EGFR degradation [25]. In addition, 
it has been reported that increased cross-linking induced 
by monoclonal antibody combinations inhibits endosomal 
recycling to a much larger extent than single antibodies 
and accelerates lysosomal degradation of EGFR [10, 12]. 
Our results actually show that imgatuzumab combined 
with cetuximab increases clustering of receptor-antibody 
complexes and enhances (lysosomal) EGFR degradation, 
thereby reducing membranous turnover of EGFR.
ADCC has been described as a major mechanism of 
action for immunotherapy with human IgG1 molecules. 
The glycosylation status of an antibody, preferentially 
IgG1, is important for its ability to bind to Fcγ-
receptors expressed on human immune effector cells, 
thereby enhancing the ADCC response [26, 27]. Since 
imgatuzumab does not interfere with binding of cetuximab 
on EGFR, the total amount of monoclonal antibodies on 
the cell surface is doubled when they are coincubated. 
Therefore, it was expected that in the ADCC assay, 
where human PBMCs, antibodies and low to moderate 
EGFR expressing tumor cells were coincubated, the 
antibody combination would lead to enhanced ADCC 
[13]. However, ADCC enhancement was not observed. 
In a second ADCC assay, tumor cells were preincubated 
with monoclonal antibodies. EGFR downregulation by 
long-term treatment with imgatuzumab with or without 
cetuximab, resulted in less antibody bound to the cell 
surface. Here, we observed that ADCC responses were not 
reduced. These results indicate that the threshold to induce 
the maximum amount of ADCC in this experimental 
setting is still maintained. The possibility that the antibody 
combination has different effects on monocyte and/or 
polymorphonuclear cell-mediated ADCC than single 
antibody treatment cannot be excluded based on these 
results. Our findings are supported by earlier in vitro work 
showing that the noncompetitive anti-HER2 monoclonal 
antibody combination pertuzumab plus trastuzumab 
reduced the amount of membranous HER2 on breast 
cancer cells, but maintained ADCC activity [14, 15]. Derer 
et al. also showed, using a stably transfected hamster 
kidney cell line overexpressing different EGFR cell 
surface levels and a panel of tumor cell lines with different 
EGFR cell surface levels, that maximal NK cell-mediated 
ADCC was already achieved at low membranous EGFR 
levels [28]. EGFR antibody combinations can enhance 
CDC activities in EGFR-amplified cell lines [7, 29]. 
However, we did not observe imgatuzumab-induced CDC 
in our NSCLC cell line panel expressing low to moderate 
membranous EGFR levels. Imgatuzumab clearly induced 
CDC in high EGFR expressing A431 cells, suggesting that 
membranous EGFR levels in our NSCLC cell line panel 
were too low for anti-EGFR antibody-induced CDC.
Even though certain EGFR IgG1 monoclonal 
antibody combinations such as Sym004 and MM-151 
showed superior anticancer efficacy in several human 
tumor xenograft models, their effects on ADCC were 
only investigated in EGFR amplified cell lines [11, 
29]. Effects of lower EGFR expression levels or strong 
membranous EGFR downregulation on ADCC were not 
investigated. Our results demonstrate that even after strong 
EGFR downregulation and concomitant proliferation 
inhibition, ADCC still provides a mechanism by which 
imgatuzumab in combination with cetuximab can provide 
additional antitumor effect, especially in EGFR and KRAS 
wild-type NSCLC. A recent study showed that ADCC 
activity of imgatuzumab compared with cetuximab is 
unaffected by conventional cancer premedication drugs 
and chemotherapy agents in various xenograft models 
[30]. Although Roche stopped its imgatuzumab clinical 
programme after it failed to meet its primary endpoint 
in a phase II trial in colorectal cancer [31], it will be of 
interest to explore the combination of imgatuzumab and 
cetuximab in such treatment strategies.
In conclusion, imgatuzumab in combination with 
cetuximab leads to stronger downregulation of EGFR and 
enhances the antitumor effect in vitro. Despite lowering 
EGFR surface levels, monoclonal antibody induced 
ADCC response is maintained. These findings support 
further clinical exploration of the antibody combination in 
EGFR wild-type NSCLC.
MATERIALS AND METHODS
Cells, antibodies and drugs
The human NSCLC cell lines SW-1573, H292, 
A549, H358 and H441, and the squamous-cell carcinoma 
A431 were obtained from the American Type Culture 
Collection (ATCC). H322 was obtained from Sigma-
Aldrich. All cell lines are EGFR wild-type and H441, 
H358, SW-1573 and A549 are KRAS-mutant. Cells were 
quarantined until screening for microbial contamination 
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and mycoplasma was performed and proven to be 
negative. Cells were tested and authenticated in April 
2015 by Baseclear using STR profiling. NSCLC cell lines 
were cultured in RPMI media in the presence of 10% fetal 
calf serum (FCS) with (SW-1573, H322 and H441) or 
without 2 mM L-glutamine (A549, H358 and H292) and 
incubated at 37 °C in a humidified atmosphere with 5% 
CO2. A431 cells were cultured in DMEM high glucose in 
the presence of 10% FCS. Commercial-grade cetuximab 
was purchased from Merck. Imgatuzumab (GA201) and 
the nonglycoengineered version of GA201 (GA201wt) 
were provided by Roche (13). For monoclonal antibody 
treatments a total concentration of 20 µg/mL was used 
unless otherwise indicated. Erlotinib (LC Laboratories) 
and bafilomycin A1 (Sigma-Aldrich) were dissolved in 
dimethyl sulfoxide (DMSO), stored at −20 °C and diluted 
in fresh medium for use. The final concentration of DMSO 
never exceeded 0.1% v/v. Recombinant human EGF was 
obtained from R & D Systems.
Flow cytometry
Analysis of EGFR expression in the cancer cell lines 
was performed using flow cytometry. Cells were harvested 
in phosphate-buffered saline (PBS: 9.7 mM Na2HPO4, 
1.6 mM KH2PO4, 150 mM NaCl, pH = 7.2) containing 
2% FCS (FACS buffer) and left on ice prior to flow 
cytometry analysis. EGFR membrane expression levels 
were measured using the anti-EGFR human antibody 
imgatuzumab or cetuximab at final concentrations of 20 
μg/mL in FACS medium. Bound antibody was detected 
using mouse anti-human FITC (Sigma-Aldrich) diluted 
1:50 in FACS medium.
To determine the effects of anti-EGFR monoclonal 
antibody treatment on EGFR membrane levels, cells 
were treated with imgatuzumab (20 µg/mL), cetuximab 
(20 µg/mL) or the combination (10 µg/mL each or 20 
µg/mL each) for 24 and 72 hours. Cells were harvested 
in FACS buffer and left on ice prior to flow cytometry 
analysis. To determine the internalization of EGFR 
monoclonal antibodies and membranous turnover of 
EGFR in tumor cells, cells were stained on ice with 
the primary antibodies against EGFR (20 µg/mL final 
concentration). After staining with the primary antibody; 
1) cells were washed with ice-cold FACS buffer and 
incubated with the secondary antibody for 1 hour at 4 
˚C to measure surface expression. 2) Cells were washed 
with ice-cold FACS buffer, incubated in culture medium 
at 37 ˚C for 1, 2, or 4 hours and subsequently incubated 
with the secondary antibody for 1 hour at 4 ˚C to measure 
non-internalized EGFR-antibody complexes since the 
secondary antibodies only bind to surface bound EGFR 
antibody. The lower the amount of non-internalized 
EGFR-antibody complexes, the more internalization of 
EGFR-antibody complexes. 3) Cells were washed with 
ice-cold FACS buffer, incubated in culture medium at 
37 ˚C for 1, 2, or 4 hours and subsequently incubated with 
the primary antibody, followed by the secondary antibody 
to measure non-internalized, reappeared receptors and 
possible de novo synthesis of receptors. Duplicate samples 
were measured for each treatment condition, and corrected 
for background fluorescence and unspecific binding of 
the secondary antibody. Measurement was performed on 
a BD FACSCalibur or BD Accuri C6 (BD Biosciences). 
Data analysis was performed with FlowJo v10 (Tree Star) 




After appropriate treatment, cells were washed 
two times with ice-cold PBS and lyzed using ice-cold 
Mammalian Protein Extraction Reagent (M-PER) 
(Thermo Scientific) supplemented with phosphatase and 
protease inhibitors according to supplemented protocol. 
During the incubation for 60 minutes on ice, cells were 
scraped and the cellular contents were transferred to 
microcentrifuge tubes and stored at -20 °C until analysis. 
Protein concentrations were measured using the Bradford 
protein assay.
Western blot analysis
Protein samples from total cell lysates (20 or 50 
μg) were subjected to electrophoretic separation on a 
7.5 or 10% polyacrylamide gel and transblotted onto a 
polyvinylidine fluoride (PVDF) membrane (Millipore). 
Blots were blocked at room temperature for 1 hour in 
Tris-buffered saline (TBS)/Tween 20 (TBS-T) (0.05%) 
containing 5% bovine serum albumin (BSA) and incubated 
with: 1:500 rabbit polyclonal anti-EGFR (#2235); 1:500 
rabbit monoclonal anti-phospho-EGFR (Tyr1173) (#4407); 
1:500 rabbit monoclonal anti-phospho-EGFR (Tyr1068) 
(#3777); 1:1000 mouse monoclonal antibody anti-
phospho-p44/42 MAPK (ERK1/2) (#9106); 1:1000 rabbit 
polyclonal anti-p44/42 MAPK (ERK1/2) (#9102); 1:1000 
rabbit polyclonal anti-phospho-Akt (Thr308) (#9275); 
1:1000 rabbit polyclonal anti-Akt (#9272) (Cell Signaling 
Technology); 1:10000 mouse monoclonal anti-actin (clone 
C4) (MP Biomedicals). Blots were subsequently washed 
and incubated with HRP-anti-mouse or HRP-anti-rabbit 
antibodies at 1:1500 (Dako). Detection was performed 
using Lumi-Light Western blotting substrate (Roche 
Diagnostics Nederland B.V.). Images were captured using 
a digital imaging system (Bio-Rad).
Immunofluorescence
Imgatuzumab was directly labeled with Dylight 
633-NHS ester (Thermo Scientific). The imgatuzumab 
buffer was exchanged using 30 kDa polyethersulfone 2 
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mL Vivaspin-2 filters (Sartorius) to 0.9% NaCl, pH was 
adjusted to 8.5 and a 10-fold excess of DyLight-633 in 
DMSO was added. After 1 hour of incubation, antibody-
dye conjugates were purified from unreacted dye using 
Vivaspin centrifugal filters.
For the detection of unlabeled anti-EGFR 
monoclonal antibodies an anti-human Alexa 488 
secondary antibody (Life Technologies) was used. The 
antibodies against endosomal markers, early endosome 
antigen 1 (EEA1) (#2411, Cell Signaling Technology) 
and lysosomal-associated membrane protein 1 (LAMP1) 
(H4A3) (Santa Cruz Biotechnology) at 1:200 were 
detected using Alexa 647-labeled secondary antibodies 
(Life Technologies). To investigate endocytic trafficking, 
H292 and SW-1573 cells were seeded in 24 wells plates 
on glass cover slides coated with poly-L-lysine (Sigma-
Aldrich). After incubation with the anti-EGFR monoclonal 
antibodies cells were fixed, permeabilized using 0.1% 
Triton X-100 (Sigma-Aldrich) and blocked with bovine 
serum albumin. Cells were incubated overnight with 
primary antibodies against endosomal markers at 4 °C 
and with secondary fluorescent antibodies for 30 minutes 
at room temperature. For the Lamp1 staining additional 
cetuximab and/or imgatuzumab were added to visualize 
total EGFR. After the DAPI staining (Sigma-Aldrich) 
cells were mounted using Kaiser’s Glycerin (Brunschwig 
Chemie) and examined using a Leica TCS SP8 confocal 
microscope (Leica, Wetzlar).
Growth inhibition and migration assays
For the proliferation assays, SW-1573 (2000 cells/
well), H292 (2000 cells/well), H322 (8000 cells/well), 
A549 cells (2000 cells/well) and H358 (2000 cells/well) 
were seeded in 12 wells plates. Cells were allowed to 
adhere overnight. Subsequently, cells were treated with the 
indicated anti-EGFR monoclonal antibodies (20 µg/mL 
total) in complete medium containing 10% FCS with or 
without the addition of 1 or 10 ng/mL EGF and incubated 
for the indicated time period at 37 °C.
For the wound healing assays, H292 and A549 cells 
(both 150,000 cells/well) were seeded in 24 wells plates. 
After 24 hours cells were serum starved overnight. Next, 
a scratch was made in the monolayer with a pipette tip, 
wells were washed with PBS, and cells incubated in serum 
free medium containing 10 ng/mL EGF with or without 
the anti-EGFR monoclonal antibodies at 37 °C. Scratch 
area was measured when the scratch was made and after 
16 hours for H292 or 24 hours for A549 using Image J 
software analysis (1.47v).
ADCC assays
ADCC was measured using the Lactose 
Dehydrogenase Cytotoxicity Detection Kit (Roche 
Diagnostics) according to standard protocol as described 
previously [13]. Briefly, human PBMCs were prepared 
from healthy blood donors by Ficoll (GE Healthcare) 
gradient centrifugation. PBMCs were washed in PBS and 
resuspended in Aim V medium (Life Technologies). Serial 
dilutions of either imgatuzumab or cetuximab were added 
to each well of a 96-well plate. The final concentration 
of the monoclonal antibody combination was the same as 
in the single monoclonal antibody experiments. ADCC 
was conducted using an effector:target (E:T) cell ratio 
of 25:1 and 4 hours incubation at 37 °C. All assays were 
conducted in triplicate.
CDC assays
CDC was measured using the Lactose 
Dehydrogenase Cytotoxicity Detection Kit (Roche 
Diagnostics). Anti-EGFR monoclonal antibodies (10 µg/
mL total) were added to 25.000 tumors cells in a 96-well 
plate. CDC was conducted using a final concentration of 
5% freshly drawn human serum and 4 hours incubation 
at 37 °C. Antibody-dependent cytotoxicity without serum 
was not observed. All assays were conducted in triplicate.
Statistics
In vitro data were assessed for differences with 
unpaired two-tailed Student’s t-test or two-way ANOVA 
followed by Bonferroni post-test. Results are represented as 
means ± SD. A P-value < 0.05 was considered significant. 
Statistical analyses were generated using GraphPad Prism 
software (version 5.0 GraphPad software).
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